Matoka Derek J, Averch Timothy D
Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213-3232, USA.
Can J Urol. 2007 Oct;14(5):3710-4.
Photoselective laser vaporization of the prostate (PVP) is recognized as an alternative for the surgical management of BPH. Our experience suggests a higher incidence of persistent irritative symptoms than expected. Characteristics of our population were evaluated to determine whether postoperative symptomatology could be predicted.
We retrospectively reviewed those patients who underwent PVP at our institution between June 2004 and February 2006. Lower urinary tract symptoms as measured by the American Urological Association Symptom Index (AUA-SI) score and quality of life (QoL) score were recorded. In addition, peak urinary flow rate (Qmax) and ultrasound prostate volumes were also measured. PVP was performed using an 80 W KTP side-firing laser (LaserScope, San Jose, CA). Total energy used was recorded. AUA-SI score, QoL and Qmax were monitored at 1, 3 and 6 months postoperatively.
Twenty-nine men were evaluated retrospectively. Their mean AUA-SI score, prostate volume and energy used were 17.8, 49.8 cm3 and 96.8 kJ respectively. At 1 month, 34 % complained of significant urgency, frequency and dysuria. Anticholinergic therapy was initiated in six patients. At 6 months, the number of patients complaining of symptoms decreased to 17% and five of the six patients were no longer requiring therapy. An association between finasteride therapy prior to PVP and post-operative symptoms was identified. In our series, 70% of those patients experiencing persistent symptoms had been managed with finasteride. No association between irritative voiding symptoms, laser energy utilized and volume of treated prostate gland was observed. However, a statistically significant association was noted between persistent irritative voiding symptoms and both lower preoperative AUA-SI scores and preoperative use of finasteride.
Although a therapeutic benefit is observed following PVP, persistent irritative voiding symptoms are not uncommon. Lower preoperative AUA-SI scores and treatment with finasteride appear to be associated with bothersome postoperative symptoms. This information can be used to effectively select candidates and to counsel those patients with regard to both the therapeutic objective and expectations related to this procedure.
前列腺光选择性汽化术(PVP)被认为是良性前列腺增生(BPH)手术治疗的一种替代方法。我们的经验表明,持续性刺激性症状的发生率高于预期。对我们研究人群的特征进行评估,以确定是否可以预测术后症状。
我们回顾性分析了2004年6月至2006年2月在我院接受PVP的患者。记录通过美国泌尿外科学会症状指数(AUA-SI)评分和生活质量(QoL)评分所测量的下尿路症状。此外,还测量了最大尿流率(Qmax)和超声前列腺体积。使用80W的KTP侧射激光(LaserScope,圣何塞,加利福尼亚州)进行PVP。记录所使用的总能量。在术后1、3和6个月监测AUA-SI评分、QoL和Qmax。
对29名男性进行了回顾性评估。他们的平均AUA-SI评分、前列腺体积和所使用的能量分别为17.8、49.8cm³和96.8kJ。在1个月时,34%的患者抱怨有明显的尿急、尿频和尿痛。6名患者开始接受抗胆碱能治疗。在6个月时,抱怨症状的患者数量降至17%,6名患者中有5名不再需要治疗。确定了PVP术前使用非那雄胺治疗与术后症状之间的关联。在我们的系列研究中,出现持续性症状的患者中有70%曾接受非那雄胺治疗。未观察到刺激性排尿症状、所使用的激光能量与治疗的前列腺体积之间的关联。然而,观察到持续性刺激性排尿症状与术前较低的AUA-SI评分和术前使用非那雄胺之间存在统计学上的显著关联。
尽管PVP术后观察到有治疗益处,但持续性刺激性排尿症状并不罕见。术前较低的AUA-SI评分和非那雄胺治疗似乎与令人烦恼的术后症状有关。这些信息可用于有效选择患者,并就该手术的治疗目标和预期向患者提供咨询。